Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy

다국어 초록 (Multilingual Abstract)

Purpose Fractionated radiotherapy as well as concomitant and adjuvant chemotherapy such as temozolomide for postoperative high-grade glioma (HGG) patients improves progressionfree survival and overall survival. Multiple factors such as chemotherapy, radiotherapy, tumor grade, residual tumor volume, and genetic modifications might play a role in the formation of cognitive impairment. The risk factors of cognitive impairment in postoperative patients with HGG receiving radiotherapy and chemotherapy remains a concern in this population.
The purpose of this study was to identify risk factors for cognitive impairment in patients of postoperative HGG.
Materials and Methods A total of 229 patients with HGG who underwent surgery were analyzed. Cognitive impairment was defined as a decrease of Cognitive Assessment Montreal (MoCA)’s score in at least two cognitive domains or any MoCA’s score of less than 26 points at the time of study compared with baseline level. Multiple potential risk factors including methylated status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter, glioma World Health Organization (WHO) grade, residual tumor volume, education, and sex were analyzed. Cox univariate and multivariate regression analysis was used to detect the significant risk factors for cognitive impairment.
Results At the end of follow-up among the 229 patients, 147 patients (67%) developed cognitive impairment. 82 patients (36%) remained in normal cognitive condition. In multivariate analysis, unmethylated MGMT promoter (hazard ratio [HR], 1.679; 95% confidence interval [CI], 1.212 to 2.326; p=0.002), glioblastoma (HR, 1.550; 95% CI, 1.117 to 2.149; p=0.009), and residual tumor volume > 5.58 cm3 (HR, 1.454; 95% CI, 1.047 to 2.020; p=0.026) were independent risk factors for cognitive impairment.
Conclusion Methylated status of the MGMT promoter, glioma WHO grade, and residual tumor volume might be risk factors for the cognitive impairment in postoperative patients with HGG.

참고문헌 (Reference)

1 Saito K, "Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma : a retrospective study" 54 : 272-279, 2014

2 Sarkissian V, "The sequelae of cranial irradiation on human cognition" 382 : 118-123, 2005

3 Binabaj MM, "The prognostic value of MGMT promoter methylation in glioblastoma : a meta-analysis of clinical trials" 233 : 378-386, 2018

4 Kesler SR, "The effect of IDH1 mutation on the structural connectome in malignant astrocytoma" 131 : 565-574, 2017

5 Nasreddine ZS, "The Montreal Cognitive Assessment, MoCA : a brief screening tool for mild cognitive impairment" 53 : 695-699, 2005

6 Smith T, "The Montreal Cognitive Assessment : validity and utility in a memory clinic setting" 52 : 329-332, 2007

7 Verger E, "Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases : a phase II randomized trial" 61 : 185-191, 2005

8 Noll KR, "Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection" 17 : 580-587, 2015

9 Dhermain F, "Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches" 33 : 16-24, 2014

10 Antonadou D, "Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases" 20 : 3644-3650, 2002

11 Jiang X, "O6-methylguanine-DNA methyltransferase(MGMT)immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma" 114 : 135-140, 2013

12 Wefel JS, "Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection" 18 : 1656-1663, 2016

13 Klein M, "Neurobehavioral status and healthrelated quality of life in newly diagnosed high-grade glioma patients" 19 : 4037-4047, 2001

14 Smrdel U, "Long-term survival in glioblastoma : methyl guanine methyl transferase(MGMT)promoter methylation as independent favourable prognostic factor" 50 : 394-401, 2016

15 Armstrong CL, "Late cognitive and radiographic changes related to radiotherapy : initial prospective findings" 59 : 40-48, 2002

16 Liu Y, "Genetic modulation of neurocognitive function in glioma patients" 21 : 3340-3346, 2015

17 Durand T, "EpiBrainRad : an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients" 15 : 261-, 2015

18 Klein M, "Effect of radiotherapy and other treatmentrelated factors on mid-term to long-term cognitive sequelae in low-grade gliomas : a comparative study" 360 : 1361-1368, 2002

19 Woo PY, "Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy : a multicenter cohort study" 63 : 134-141, 2019

20 Kole AJ, "Concurrent chemoradiotherapy versus radiotherapy alone for"biopsy-only"glioblastoma multiforme" 122 : 2364-2370, 2016

21 김병섭, "Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea" 대한암학회 49 (49): 193-203, 2017

22 Miotto EC, "Cognitive impairments in patients with low grade gliomas and high grade gliomas" 69 : 596-601, 2011

23 Laack NN, "Cognitive function after radiotherapy for supratentorial low-grade glioma : a North Central Cancer Treatment Group prospective study" 63 : 1175-1183, 2005

24 Talacchi A, "Cognitive effects of tumour and surgical treatment in glioma patients" 103 : 541-549, 2011

25 Tucha O, "Cognitive deficits before treatment among patients with brain tumors" 47 : 324-333, 2000

26 Wang M, "Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402" 77 : 662-669, 2010

27 Yang K, "Cancer genetic markers according to radiotherapeutic response in patients with primary glioblastoma : radiogenomic approach for precision medicine" 131 : 66-74, 2019

28 Ostrom QT, "CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012" 17 (17): iv1-iv62, 2015

29 Surma-aho O, "Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients" 56 : 1285-1290, 2001

30 Wang Q, "A prospective longitudinal evaluation of cognition and depression in postoperative patients with high-grade glioma following radiotherapy and chemotherapy" 14 (14): S1048-S1051, 2018